Viking Therapeutics Inc’s recent filing unveils that its President & CEO Lian Brian unloaded Company’s shares for reported $8.31 million on Jan 06 ’25. In the deal valued at $42.75 per share,194,490 shares were sold. As a result of this transaction, Lian Brian now holds 2,366,570 shares worth roughly $77.51 million.
Then, Mancini Marianna sold 54,215 shares, generating $2,317,599 in total proceeds. Upon selling the shares at $42.75, the Chief Operating Officer now owns 374,134 shares.
Before that, ZANTE GREG sold 50,309 shares. Viking Therapeutics Inc shares valued at $2,150,595 were divested by the Chief Financial Officer at a price of $42.75 per share. As a result of the transaction, ZANTE GREG now holds 165,259 shares, worth roughly $5.41 million.
Piper Sandler initiated its Viking Therapeutics Inc [VKTX] rating to an Overweight in a research note published recently. A number of analysts have revised their coverage, including B. Riley Securities’s analysts, who began to cover the stock in late November with a ‘”a Buy”‘ rating. H.C. Wainwright also remained covering VKTX and reiterated its “Buy” recommendation on November 04, 2024. JP Morgan started covering the stock on September 11, 2024. It rated VKTX as “an Overweight”.
Price Performance Review of VKTX
On Friday, Viking Therapeutics Inc [NASDAQ:VKTX] saw its stock fall -2.79% to $32.75. Over the last five days, the stock has lost -5.07%. Viking Therapeutics Inc shares have fallen nearly -18.61% since the year began. Nevertheless, the stocks have risen 37.49% over the past one year. While a 52-week high of $99.41 was reached on 01/06/25, a 52-week low of $22.51 was recorded on 01/21/25. SMA at 50 days reached $43.09, while 200 days put it at $57.23.
Levels Of Support And Resistance For VKTX Stock
The 24-hour chart illustrates a support level at 31.76, which if violated will result in even more drops to 30.77. On the upside, there is a resistance level at 34.26. A further resistance level may holdings at 35.77. The Relative Strength Index (RSI) on the 14-day chart is 32.29, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.77, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 75.23%. Stochastics %K at 27.79% indicates the stock is a holding.
How much short interest is there in Viking Therapeutics Inc?
A steep rise in short interest was recorded in Viking Therapeutics Inc stocks on 2025-01-15, growing by 1.9 million shares to a total of 20.2 million shares. Yahoo Finance data shows the prior-month short interest on 2024-12-13 was 18.3 million shares. There was a rise of 9.43%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on June 27, 2024 when Morgan Stanley began covering the stock and recommended ‘”an Overweight”‘ rating along with a $105 price target.
